| Title: |
Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol |
| Authors: |
Gillessen, Silke; Murphy, Laura; James, Nicholas D; Sachdeva, Ashwin; El-Taji, Omar; Abdel-Aty, Hada; Adler, Amanda I; Amos, Claire; Attard, Gerhardt; Varughese, Mohini; Gale, Joanna; Brown, Simon; Srihari, Narayanan; Birtle, Alison; Brown, Mick; al., et |
| Publisher Information: |
Elsevier |
| Publication Year: |
2025 |
| Collection: |
University of Central Lancashire: CLOK - Central Lancashire Online Knowledge |
| Subject Terms: |
A300 - Clinical medicine |
| Description: |
Background Metformin is a widely used anti-diabetic drug. Several studies have suggested that metformin has anticancer activity in some malignancies, including prostate cancer. Metformin might also mitigate the adverse metabolic effects of androgen-deprivation therapy (ADT). We hypothesised that metformin might improve survival in patients with metastatic hormone-sensitive prostate cancer and reduce metabolic complications associated with ADT. Methods The STAMPEDE multi-arm, multi-stage, randomised phase 3 trial recruited patients with high-risk locally advanced or metastatic adenocarcinoma of the prostate staged by conventional imaging with isotope bone and CT scanning. This publication reports findings for the most recent STAMPEDE research question, testing the addition of metformin to standard of care for non-diabetic (glycated haemoglobin [HbA1c] |
| Document Type: |
article in journal/newspaper |
| File Description: |
application/pdf |
| Language: |
English |
| ISSN: |
1470-2045 |
| Relation: |
https://clok.uclan.ac.uk/id/eprint/56363/9/56363%20Gillessen%20et%20al.%20VOR.pdf; Gillessen, Silke, Murphy, Laura, James, Nicholas D, Sachdeva, Ashwin, El-Taji, Omar, Abdel-Aty, Hada, Adler, Amanda I, Amos, Claire, Attard, Gerhardt et al (2025) Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol. The Lancet Oncology, 26 (8). pp. 1018-1030. ISSN 1470-2045 |
| DOI: |
10.1016/S1470-2045(25)00231-1 |
| Availability: |
https://clok.uclan.ac.uk/id/eprint/56363/; https://clok.uclan.ac.uk/id/eprint/56363/9/56363%20Gillessen%20et%20al.%20VOR.pdf; https://doi.org/10.1016/S1470-2045(25)00231-1 |
| Rights: |
cc_by_nc_nd_4 |
| Accession Number: |
edsbas.4AE4B807 |
| Database: |
BASE |